Showing results (241-250 of 253) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?Elizabeth A Richey, E Alison Lyons, Jonathan R Nebeker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineThomas J Smith, James Khatcheressian, Gary H Lyman, et al.Journal of the American College of Cardiology|September 18, 2007
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR ProjectCharles L Bennett, Benjamin Kim, Anaadriana Zakarija, et al.Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.JAMA|March 4, 2008
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett, Samuel M Silver, Benjamin Djulbegovic, et al.The Oncologist|March 8, 2019
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and CanadaBrian Chen, Sumimasa Nagai, James O Armitage, et al.Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.Nature Communications|September 24, 2020
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes developmentJayakrishna Ambati, Joseph Magagnoli, Hannah Leung, et al.Blood|March 7, 2009
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectKenneth R Carson, Andrew M Evens, Elizabeth A Richey, et al.The Journal of Community and Supportive Oncology|March 9, 2016
Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social networkKamaljeet Kaur, Raja Fayad, Arpit Saxena, et al.Pageof 26